Vascular Therapies
in the News

Vascular Therapies Completes Enrollment in the ACCESS 2 Study, a Phase III Multinational Randomized Clinical Trial of the Sirolimus Eluting Collagen Implant (Sirogen™) for the Surgical Creation of Arteriovenous Fistula for Hemodialysis Vascular Access

AUG 5, 2024

Vascular Therapies Initiates Enrollment in ACCESS 2 Clinical Trial

Aug 29, 2022

Vascular Therapies Completes $25 Million Private Financing

March 29, 2022

Vascular Therapies Announces Presentation of Phase 3 Clinical Trial Results at the American Society of Nephrology Meeting

November 4, 2021

Vascular Therapies to Participate in the SVB Leerink 9th Annual Global Healthcare Conference

February 11, 2020

Vascular Therapies Completes Upsized $17.3 Million Private Financing

January 28, 2020

Vascular Therapies Announces Positive Preliminary Clinical Results from its AV Fistula Trials in Patients with Kidney Disease

September 5, 2019

Vascular Therapies Announces Completion of Enrollment in the ACCESS Study, a U.S. Phase III Clinical Trial

August 19, 2019

Vascular Therapies Appoints John McDermott as Chief Executive Officer

January 15, 2019